AMG 531

Phase 3Biologic

Amgen

AMG 531 is one of 139 biologic programs targeting Thrombocytopenic Purpura. It is currently in Phase 3.

Indications

Total Trials

Active Trials

138

Competitors

Pipeline

Status by Indication[3][1]

Indication

Thrombocytopenic PurpuraActive, not recruiting

ThrombocytopeniaActive, not recruiting

LymphomaActive, not recruiting

Myelodysplastic SyndromeActive, not recruiting

Thrombocytopenic PurpuraPhase 3

Active, not recruiting

ThrombocytopeniaPhase 1/Phase 2

Active, not recruiting

LymphomaPhase 1/Phase 2

Active, not recruiting

Myelodysplastic SyndromePhase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

AMG 531

Amgen

Phase 3

1 2

Oncaspar

SServier

Preclinical

15 3

Norvir

AbbVie

Preclinical

1 4

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Decadron

QQuince Therapeutics S.p.A.

PEG-Intron

1 9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—10

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Thrombocytopenic Purpura3 trials

AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy

Completed· Amgen logo

Amgen·Phase 3·NCT00102323·63 enrolled

P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura

Completed· Amgen logo

Amgen·Phase 3·NCT00603642·34 enrolled

AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy

Completed· Amgen logo

Amgen·Phase 3·NCT00102336·62 enrolled

Myelodysplastic Syndrome2 trials

Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents

Completed· Amgen logo

Amgen·Phase 2·NCT00321711·69 enrolled

A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid

Completed· Amgen logo

Amgen·Phase 2·NCT00418665·39 enrolled

ITP1 trial

Open Label Extension Study of AMG 531 in Japanese Subjects With ITP

Completed· Kyowa Kirin Co., Ltd. logo

Kyowa Kirin Co., Ltd.·Phase 2/3·NCT00440037·44 enrolled

Lymphoma1 trial

Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00299182·50 enrolled

Thrombocytopenia1 trial

A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma

Completed· Amgen logo

Amgen·Phase 1/2·NCT00283439·39 enrolled

2 more indications

Safety and Efficacy1 trial

Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects

Completed· Amgen logo

Amgen·Phase 1/2·NCT00515203·22 enrolled

Advanced Malignancy1 trial

AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00147225·55 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for AMG 531. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AMG 531 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AMG 531. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Amgen

AMG 531

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Thrombocytopenic Purpura3 trials

Myelodysplastic Syndrome2 trials

ITP1 trial

Lymphoma1 trial

Thrombocytopenia1 trial

Safety and Efficacy1 trial

Advanced Malignancy1 trial

References

Drug Info

Quick Facts

Related News